ProQuest Investments
ProQuest Investments is a New Jersey-based venture capital firm seeking to finance seed- to late-stage healthcare companies.
Business Model: B2B
Revenue: $15.3M
Employees: 2-10
Rankings
Industries / Tags:
Detailed ProQuest Investments Information
Geographic Data
Address: 2430 Vanderbilt Beach Rd
City: Naples
State: FL
Zip: 34109
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management. We have 12 deal professionals and three offices, our headquarters in Princeton, and additional offices in San Diego and Montreal. We invest in healthcare companies seeking financings ranging from seed to late-stage. Our portfolio reflects the rich diversity of the healthcare industry and exemplifies our commitment to fostering the growth of exceptional businesses. In addition to our breadth of experience across many sectors of the healthcare industry, we have special expertise in therapeutics, where innovations in drug discovery technologies and molecular analysis are transforming an enormous unmet medical need. With a proven superior track record and over 40 investments in such diverse therapeutic categories as oncology, pain and infectious disease, ProQuest Investments seeks to build long term, mutually beneficial partnerships with outstanding entrepreneurs. At the end of 2006, ProQuest Investments closed its fourth fund of $425 million.
Contact Phone:
+16099193560
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2013 | ReVision Optics | Equity | 15M |
| 11/2014 | SomaLogic | Venture Round | 0 |
| 9/2011 | MethylGene | Venture Round | 34.5M |
| 6/2002 | Salmedix | Series B | 27.5M |
| 10/2004 | Gloucester Pharmaceuticals | Series B | 29M |
| 6/2010 | Predictive Biosciences | Series C | 25M |
| 11/2007 | Zosano Pharma | Series A | 90M |
| 11/2007 | LEAD Therapeutics | Series A | 17M |
| 3/2007 | Adastra Pharmaceuticals | Series A | 40M |
| 4/2009 | Orthocon | Series B | 25M |
| 12/2009 | Orthocon | Venture Round | 12.5M |
| 8/2002 | Threshold Pharmaceuticals | Series A | 8.3M |
| 8/2014 | Mevion Medical Systems | Private Equity Round | 0 |
| 6/2013 | Mevion Medical Systems | Private Equity Round | 0 |
| 4/2009 | Aerovance | Venture Round | 38M |
| 1/2003 | Iomai Corporation | Series C | 54M |
| 12/2005 | Optimer Pharmaceuticals | Series D | 22.2M |
| 9/2008 | Telormedix | Series A | 0 |
| 1/2004 | Threshold Pharmaceuticals | Series B | 41M |
| 8/2009 | Gloucester Pharmaceuticals | Series D | 29M |
| 8/2009 | Biosyntech | Venture Round | 1.4M |
| 1/2018 | SomaLogic | Venture Round | 0 |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 12/2002 | BioRexis | Series A | 8M |
| 12/2006 | NovaDel Pharma Inc | Venture Round | 0 |
| 2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
| 7/2005 | EUSA Pharma | Venture Round | 14M |
| 5/2006 | Alaunos Therapeutics | Post-IPO Equity | 0 |
| 10/2013 | Immune Design | Series C | 49M |
| 1/2012 | Telormedix | Series B | 0 |
| 9/2001 | Optimer Pharmaceuticals | Series B | 32M |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2008 | Gemin X Pharmaceuticals | Series C | 38M |
| 8/2009 | Zosano Pharma | Series B | 30M |
| 4/2010 | Adastra Pharmaceuticals | Venture Round | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 1/2008 | Sopherion Therapeutics | Venture Round | 0 |
| 11/2005 | Guava Technologies | Venture Round | 7M |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 7/2012 | Agile Therapeutics | Series C | 0 |
| 6/2010 | Agile Therapeutics | Series B | 0 |
| 2/2007 | Alaunos Therapeutics | Post-IPO Equity | 0 |
| 1/2012 | Mevion Medical Systems | Venture Round | 0 |
| 7/2012 | Mersana Therapeutics | Series A | 27M |
| 11/2007 | Excaliard Pharmaceuticals | Series A | 15.5M |
| 6/2001 | Guava Technologies | Series B | 17.5M |
| 12/2013 | Telormedix | Series B | 0 |
| 7/2010 | ReVision Optics | Series D | 35M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 12/1998 | Acurian | Series A | 6M |
| 11/2010 | Aires Pharmaceuticals | Series B | 20M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 7/2010 | Immune Design | Series B | 32M |
| 1/2004 | Novacea | Series C | 35M |
| 11/2002 | Novacea | Series B | 36M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 11/2005 | Mersana Therapeutics | Venture Round | 21M |
| 1/2018 | SomaLogic | Venture Round | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
| 11/2014 | SomaLogic | Venture Round | 0 |
| 8/2014 | Mevion Medical Systems | Private Equity Round | 0 |
| 12/2013 | Telormedix | Series B | 0 |
| 10/2013 | Immune Design | Series C | 0 |
| 7/2013 | ReVision Optics | Series E | 0 |
| 6/2013 | Mevion Medical Systems | Private Equity Round | 0 |
| 4/2013 | ReVision Optics | Series E | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
